Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world retrospective study of adjuvant icotinib after resection in high-risk stage IA2 to IB EGFR-mutant non-small cell lung cancer
CTR20262803Phase 4Active
- Sponsor
- Betta Pharmaceuticals
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Jul 2026; status: active.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262803.